Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2021

Open Access 01-12-2021 | Metformin | Review

How metformin affects various malignancies by means of microRNAs: a brief review

Authors: Nahid Alimoradi, Negar Firouzabadi, Reihaneh Fatehi

Published in: Cancer Cell International | Issue 1/2021

Login to get access

Abstract

Metformin known as the first-line orally prescribed drug for lowering blood glucose in type II diabetes (T2DM) has recently found various therapeutic applications including in cancer. Metformin has been studied for its influences in prevention and treatment of cancer through multiple mechanisms such as microRNA (miR) regulation. Alteration in the expression of miRs by metformin may play an important role in the treatment of various cancers. MiRs are single-stranded RNAs that are involved in gene regulation. By binding to the 3′UTR of target mRNAs, miRs influence protein levels. Irregularities in the expression of miRs that control the expression of oncogenes and tumor suppressor genes are associated with the onset and progression of cancer. Metformin may possess an effect on tumor prevention and progression by modifying miR expression and downstream pathways. Here, we summarize the effect of metformin on different types of cancer by regulating the expression of various miRs and the associated downstream molecules.
Literature
1.
2.
Viollet B, Guigas B, Garcia NS, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci. 2012;122(6):253–70.CrossRef
3.
Lei Y, Yi Y, Liu Y, Liu X, Keller ET, Qian C-N, et al. Metformin targets multiple signaling pathways in cancer. Chin J Cancer. 2017;36(1):1–9.CrossRef
4.
Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. Ann Transl Med. 2014;2(6).
5.
Re M, Magliulo G, Gioacchini FM, Bajraktari A, Bertini A, Çeka A, et al. Expression levels and clinical significance of miR-21-5p, miR-let-7a, and miR-34c-5p in laryngeal squamous cell carcinoma. BioMed Res Intern. 2017;1:1–9.CrossRef
6.
Do MT, Kim HG, Khanal T, Choi JH, Kim DH, Jeong TC, et al. Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways. Toxicol Appl Pharmacol. 2013;271(2):229–38.PubMedCrossRef
7.
Sahra IB, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Can Res. 2011;71(13):4366–72.CrossRef
8.
Demirsoy İH, Ertural DY, Balci Ş, Çınkır Ü, Sezer K, Tamer L, et al. Profiles of circulating miRNAs following metformin treatment in patients with type 2 diabetes. J Med Biochem. 2018;37(4):499–506.PubMedPubMedCentralCrossRef
9.
Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20(5):515–24.PubMedCrossRef
10.
11.
Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460–9.PubMedCrossRef
12.
Shen S, Sun Q, Liang Z, Cui X, Ren X, Chen H, et al. A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status. PLoS ONE. 2014;9(6):e100664.PubMedPubMedCentralCrossRef
13.
Jin L, Wessely O, Marcusson EG, Ivan C, Calin GA, Alahari SK. Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-α in breast cancer. Can Res. 2013;73(9):2884–96.CrossRef
14.
Takahashi R-U, Miyazaki H, Takeshita F, Yamamoto Y, Minoura K, Ono M, et al. Loss of microRNA-27b contributes to breast cancer stem cell generation by activating ENPP1. Nat Commun. 2015;6:7318.PubMedCrossRef
15.
Ludovico O, Farina M, Copetti M, Palena A, Proto V, Marotta V, et al. ENPP1 mRNA levels in white blood cells and prediction of metformin efficacy in type 2 diabetic patients: a preliminary evidence. Nutr Metab Cardiovasc Dis. 2012;22(2):e5–6.PubMedCrossRef
16.
Pan J, Zhang Q, Wang Y, You M. 26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro. PLoS ONE. 2010;5(10):e13298.PubMedPubMedCentralCrossRef
17.
18.
Yang F-Q, Wang J-J, Yan J-S, Huang J-H, Li W, Che J-P, et al. Metformin inhibits cell growth by upregulating microRNA-26a in renal cancer cells. Int J Clin Exp Med. 2014;7(10):3289.PubMedPubMedCentral
19.
Yu T, Wang X-y, Gong R-g, Li A, Yang S, Cao Y-t, et al. The expression profile of microRNAs in a model of 7, 12-dimethyl-benz [a] anthrance-induced oral carcinogenesis in Syrian hamster. J Exp Clin Cancer Res. 2009;28(1):64.PubMedPubMedCentralCrossRef
20.
Deng M, Zhang R, He Z, Qiu Q, Lu X, Yin J, et al. TET-mediated sequestration of miR-26 drives EZH2 expression and gastric carcinogenesis. Can Res. 2017;77(22):6069–82.CrossRef
21.
Zhang B, Liu X-X, He J-R, Zhou C-X, Guo M, He M, et al. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis. 2011;32(1):2–9.PubMedCrossRef
22.
Chen C, Liu X, Chen C, Chen Q, Dong Y, Hou B. Clinical significance of let-7a-5p and miR-21-5p in patients with breast cancer. Ann Clin Lab Sci. 2019;49(3):302–8.PubMed
23.
Cabello P, Pineda B, Tormo E, Lluch A, Eroles P. The antitumor effect of metformin is mediated by miR-26a in breast cancer. Int J Mol Sci. 2016;17(8):1298.PubMedCentralCrossRef
24.
Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006;9(2):121–32.PubMedCrossRef
25.
Lee M, Oprea-Ilies G, Saavedra HI. Silencing of E2F3 suppresses tumor growth of Her2+ breast cancer cells by restricting mitosis. Oncotarget. 2015;6(35):37316.PubMedPubMedCentralCrossRef
26.
Wang Y, Gao X, Wei F, Zhang X, Yu J, Zhao H, et al. Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis. Gene. 2014;533(1):389–97.PubMedCrossRef
27.
Anwar SL, Sari DNI, Kartika AI, Fitria MS, Tanjung DS, Rakhmina D, et al. Upregulation of circulating MiR-21 expression as a potential biomarker for therapeutic monitoring and clinical outcome in breast cancer. Asian Pacific J Cancer Prevent APJCP. 2019;20(4):1223.CrossRef
28.
Pulito C, Mori F, Sacconi A, Goeman F, Ferraiuolo M, Pasanisi P, et al. Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities. Cell Discov. 2017;3(1):1–19.CrossRef
29.
Sharma P, Kumar S. Metformin inhibits human breast cancer cell growth by promoting apoptosis via a ROS-independent pathway involving mitochondrial dysfunction: pivotal role of superoxide dismutase (SOD). Cell Oncol. 2018;41(6):637–50.CrossRef
30.
Khalighfard S, Alizadeh AM, Irani S, Omranipour R. Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients. Sci Rep. 2018;8(1):1–11.CrossRef
31.
Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem. 2010;285(23):17869–79.PubMedPubMedCentralCrossRef
32.
Liu X, Feng J, Tang L, Liao L, Xu Q, Zhu S. The regulation and function of miR-21-FOXO3a-miR-34b/c signaling in breast cancer. Int J Mol Sci. 2015;16(2):3148–62.PubMedPubMedCentralCrossRef
33.
Queiroz EA, Puukila S, Eichler R, Sampaio SC, Forsyth HL, Lees SJ, et al. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS ONE. 2014;9(5):e98207.PubMedPubMedCentralCrossRef
34.
35.
Tan W, Tang H, Jiang X, Ye F, Huang L, Shi D, et al. Metformin mediates induction of miR-708 to inhibit self-renewal and chemoresistance of breast cancer stem cells through targeting CD47. J Cell Mol Med. 2019;23(9):5994–6004.PubMedPubMedCentralCrossRef
36.
Antolín S, Calvo L, Blanco-Calvo M, Santiago MP, Lorenzo-Patiño MJ, Haz-Conde M, et al. Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. BMC Cancer. 2015;15(1):1–15.CrossRef
37.
Zhang J, Li G, Chen Y, Fang L, Guan C, Bai F, et al. Metformin inhibits tumorigenesis and tumor growth of breast cancer cells by upregulating miR-200c but downregulating AKT2 expression. J Cancer. 2017;8(10):1849.PubMedPubMedCentralCrossRef
38.
Lu J, Hang Q, Cui Y. Reduced serum miR-142-3p predicates worse prognosis in patients with cervical cancer. Int J Clin Exp Pathol. 2017;10(3):3637–43.
39.
Xiao P, Liu W-L. MiR-142-3p functions as a potential tumor suppressor directly targeting HMGB1 in non-small-cell lung carcinoma. Int J Clin Exp Pathol. 2015;8(9):10800.PubMedPubMedCentral
40.
Xia C, Liang S, He Z, Zhu X, Chen R, Chen J. Metformin, a first-line drug for type 2 diabetes mellitus, disrupts the MALAT1/miR-142-3p sponge to decrease invasion and migration in cervical cancer cells. Eur J Pharmacol. 2018;830:59–67.PubMedCrossRef
41.
Ma C, Nong K, Zhu H, Wang W, Huang X, Yuan Z, et al. H19 promotes pancreatic cancer metastasis by derepressing let-7’s suppression on its target HMGA2-mediated EMT. Tumor Biol. 2014;35(9):9163–9.CrossRef
42.
Park S-M, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, et al. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle. 2007;6(21):2585–90.PubMedCrossRef
43.
Wang W-Y, Cao Y-X, Zhou X, Wei B, Zhan L, Fu L-T. HMGA2 gene silencing reduces epithelial–mesenchymal transition and lymph node metastasis in cervical cancer through inhibiting the ATR/Chk1 signaling pathway. Am J Transl Res. 2018;10(10):3036.PubMedPubMedCentral
44.
Chandra Gupta S, Nandan TY. Potential of long non-coding RNAs in cancer patients: from biomarkers to therapeutic targets. Int J Cancer. 2017;140(9):1955–67.PubMedCrossRef
45.
Liu K, Huang J, Ni J, Song D, Ding M, Wang J, et al. MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142-3p and miR-129-5p. Cell Cycle. 2017;16(6):578–87.PubMedPubMedCentralCrossRef
46.
Yang L, Bai H, Deng Y, Fan L. High MALAT1 expression predicts a poor prognosis of cervical cancer and promotes cancer cell growth and invasion. Eur Rev Med Pharmacol Sci. 2015;19(17):3187–93.PubMed
47.
Yan L, Zhou J, Gao Y, Ghazal S, Lu L, Bellone S, et al. Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation. Oncogene. 2015;34(23):3076.PubMedCrossRef
48.
Fujimori T, Kato K, Fujihara S, Iwama H, Yamashita T, Kobayashi K, et al. Antitumor effect of metformin on cholangiocarcinoma: in vitro and in vivo studies. Oncol Rep. 2015;34(6):2987–96.PubMedCrossRef
49.
Wandee J, Prawan A, Senggunprai L, Kongpetch S, Tusskorn O, Kukongviriyapan V. Metformin enhances cisplatin induced inhibition of cholangiocarcinoma cells via AMPK-mTOR pathway. Life Sci. 2018;207:172–83.PubMedCrossRef
50.
Masaki T, Shiratori Y, Rengifo W, Igarashi K, Yamagata M, Kurokohchi K, et al. Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology. 2003;37(3):534–43.PubMedCrossRef
51.
Kato K, Gong J, Iwama H, Kitanaka A, Tani J, Miyoshi H, et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther. 2012;11(3):549–60.PubMedCrossRef
52.
Fujihara S, Kato K, Morishita A, Iwama H, Nishioka T, Chiyo T, et al. Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo. Int J Oncol. 2015;46(5):2172–80.PubMedCrossRef
53.
Sahra IB, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27(25):3576.PubMedCrossRef
54.
Feng Y-H, Wu C-L, Shiau A-L, Lee J-C, Chang J-G, Lu P-J, et al. MicroRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells. Int J Mol Med. 2012;29(5):920–6.PubMed
55.
Kim HJ, Bar-Sagi D. Modulation of signalling by Sprouty: a developing story. Nat Rev Mol Cell Biol. 2004;5(6):441–50.PubMedCrossRef
56.
Okugawa Y, Yao L, Toiyama Y, Yamamoto A, Shigemori T, Yin C, et al. Prognostic impact of sarcopenia and its correlation with circulating miR-21 in colorectal cancer patients. Oncol Rep. 2018;39(4):1555–64.PubMed
57.
Sasaki A, Taketomi T, Kato R, Saeki K, Nonami A, Sasaki M, et al. Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1. Nat Cell Biol. 2003;5(5):427–32.PubMedCrossRef
58.
Lee C-C, Putnam AJ, Miranti CK, Gustafson M, Wang L-M, Woude GFV, et al. Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene. 2004;23(30):5193–202.PubMedCrossRef
59.
Selcuklu SD, Donoghue MT, Spillane C. miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans (Portland Press Ltd). 2009;37:918–25.CrossRef
60.
Minokoshi Y, Alquier T, Furukawa N, Kim Y-B, Lee A, Xue B, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature. 2004;428(6982):569–74.PubMedCrossRef
61.
Wang Y, Wu Z, Hu L. The regulatory effects of metformin on the [SNAIL/miR-34]:[ZEB/miR-200] system in the epithelial–mesenchymal transition (EMT) for colorectal cancer (CRC). Eur J Pharmacol. 2018;834:45–53.PubMedCrossRef
62.
Fan F, Samuel S, Evans KW, Lu J, Xia L, Zhou Y, et al. Overexpression of Snail induces epithelial–mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. Cancer Med. 2012;1(1):5–16.PubMedPubMedCentralCrossRef
63.
Xiong H, Hong J, Du W, Lin Y-w, Ren L-l, Wang Y-c, et al. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial–mesenchymal transition. J Biol Chem. 2012;287(8):5819–32.PubMedCrossRef
64.
Pan Q, Meng L, Ye J, Wei X, Shang Y, Tian Y, et al. Transcriptional repression of miR-200 family members by Nanog in colon cancer cells induces epithelial–mesenchymal transition (EMT). Cancer Lett. 2017;392:26–38.PubMedCrossRef
65.
Shi X, Kaller M, Rokavec M, Kirchner T, Horst D, Hermeking H. Characterization of a p53/miR-34a/CSF1R/STAT3 feedback loop in colorectal cancer. Cell Mol Gastroenterol Hepatol. 2020;10(2):391–418.PubMedPubMedCentralCrossRef
66.
Maierthaler M, Benner A, Hoffmeister M, Surowy H, Jansen L, Knebel P, et al. Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer. Int J Cancer. 2017;140(1):176–87.PubMedCrossRef
67.
Nugent M, Miller N, Kerin M. Circulating miR-34a levels are reduced in colorectal cancer. J Surg Oncol. 2012;106(8):947–52.PubMedCrossRef
68.
Nelson LE, Valentine RJ, Cacicedo JM, Gauthier M-S, Ido Y, Ruderman NB. A novel inverse relationship between metformin-triggered AMPK-SIRT1 signaling and p53 protein abundance in high glucose-exposed HepG2 cells. Am J Physiol Cell Physiol. 2012;303(1):C4–13.PubMedPubMedCentralCrossRef
69.
Tian X-F, Ji F-J, Zang H-L, Cao H. Activation of the miR-34a/SIRT1/p53 signaling pathway contributes to the progress of liver fibrosis via inducing apoptosis in hepatocytes but not in HSCs. PLoS ONE. 2016;11(7):e0158657.PubMedPubMedCentralCrossRef
70.
Do MT, Kim HG, Choi JH, Jeong HG. Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents. Free Radical Biol Med. 2014;74:21–34.CrossRef
71.
Cufi S, Vazquez-Martin A, Oliveras-Ferraros C, Quirantes R, Segura-Carretero A, Micol V, et al. Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205. Cell Cycle. 2012;11(6):1235–46.PubMedCrossRef
72.
Vang S, Wu H-T, Fischer A, Miller DH, MacLaughlan S, Douglass E, et al. Identification of ovarian cancer metastatic miRNAs. PLoS ONE. 2013;8(3):e58226.PubMedPubMedCentralCrossRef
73.
Kato K, Iwama H, Yamashita T, Kobayashi K, Fujihara S, FuJIMORI T, et al. The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: study of the microRNAs associated with the antitumor effect of metformin. Oncol Rep. 2016;35(3):1582–92.PubMedCrossRef
74.
Noren Hooten N, Martin-Montalvo A, Dluzen DF, Zhang Y, Bernier M, Zonderman AB, et al. Metformin-mediated increase in DICER1 regulates microRNA expression and cellular senescence. Aging Cell. 2016;15(3):572–81.PubMedPubMedCentralCrossRef
75.
McCarty MF. Metformin may antagonize Lin28 and/or Lin28B activity, thereby boosting let-7 levels and antagonizing cancer progression. Med Hypotheses. 2012;78(2):262–9.PubMedCrossRef
76.
Zhong T, Men Y, Lu L, Geng T, Zhou J, Mitsuhashi A, et al. Metformin alters DNA methylation genome-wide via the H19/SAHH axis. Oncogene. 2017;36(17):2345–54.PubMedCrossRef
77.
Ding XC, Weiler J, Großhans H. Regulating the regulators: mechanisms controlling the maturation of microRNAs. Trends Biotechnol. 2009;27(1):27–36.PubMedCrossRef
78.
Kallen AN, Zhou X-B, Xu J, Qiao C, Ma J, Yan L, et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell. 2013;52(1):101–12.PubMedCrossRef
79.
Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917–20.PubMedCrossRef
80.
King CE, Cuatrecasas M, Castells A, Sepulveda AR, Lee J-S, Rustgi AK. LIN28B promotes colon cancer progression and metastasis. Can Res. 2011;71(12):4260–8.CrossRef
81.
Peng F, Li T-T, Wang K-L, Xiao G-Q, Wang J-H, Zhao H-D, et al. H19/let-7/LIN28 reciprocal negative regulatory circuit promotes breast cancer stem cell maintenance. Cell Death Dis. 2018;8(1):e2569-e.CrossRef
82.
Heo I, Joo C, Cho J, Ha M, Han J, Kim VN. Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. Mol Cell. 2008;32(2):276–84.PubMedCrossRef
83.
Heo I, Joo C, Kim Y-K, Ha M, Yoon M-J, Cho J, et al. TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation. Cell. 2009;138(4):696–708.PubMedCrossRef
84.
Zhou J, Yang L, Zhong T, Mueller M, Men Y, Zhang N, et al. H19 lncRNA alters DNA methylation genome wide by regulating S-adenosylhomocysteine hydrolase. Nat Commun. 2015;6(1):1–13.CrossRef
85.
Guo M, Zhou JJ, Huang W. Metformin alleviates endometrial hyperplasia through the UCA1/miR-144/TGF-β1/AKT signaling pathway. Int J Mol Med. 2020;45(2):623–33.PubMed
86.
Wang W, Ge L, Xu X-J, Yang T, Yuan Y, Ma X-L, et al. LncRNA NEAT1 promotes endometrial cancer cell proliferation, migration and invasion by regulating the miR-144-3p/EZH2 axis. Radiol Oncol. 2019;53(4):434–42.PubMedPubMedCentralCrossRef
87.
Piestrzeniewicz-Ulanska D, Brys M, Semczuk A, Rechberger T, Jakowicki JA, Krajewska WM. TGF-β signaling is disrupted in endometrioid-type endometrial carcinomas. Gynecol Oncol. 2004;95(1):173–80.PubMedCrossRef
88.
Zuo Z-K, Gong Y, Chen X-H, Ye F, Yin Z-M, Gong Q-N, et al. TGFβ1-induced lncRNA UCA1 upregulation promotes gastric cancer invasion and migration. DNA Cell Biol. 2017;36(2):159–67.PubMedCrossRef
89.
Yamashita T, Kato K, Fujihara S, Iwama H, Morishita A, Yamana H, et al. Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0/G1 cell cycle arrest. Anticancer Drugs. 2020;31(3):231–40.PubMedCrossRef
90.
He D, Wang J, Zhang C, Shan B, Deng X, Li B, et al. Down-regulation of miR-675-5p contributes to tumor progression and development by targeting pro-tumorigenic GPR55 in non-small cell lung cancer. Mol Cancer. 2015;14(1):1–14.CrossRef
91.
Xu Y, Liu Y, Li Z, Li H, Li X, Yan L, et al. Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675. Oncol Rep. 2020;44(1):165–73.PubMedPubMedCentralCrossRef
92.
Saudy NS, Fawzy IM, Azmy E, Goda EF, Eneen A, Salam EMA. BMI1 gene expression in myeloid leukemias and its impact on prognosis. Blood Cells Mol Dis. 2014;53(4):194–8.PubMedCrossRef
93.
Li J, Wang Y, Ge J, Li W, Yin L, Zhao Z, et al. Doublecortin-like kinase 1 (DCLK1) regulates B cell-specific moloney murine leukemia virus insertion site 1 (Bmi-1) and is associated with metastasis and prognosis in pancreatic cancer. Cell Physiol Biochem. 2018;51(1):262–77.PubMedCrossRef
94.
Guo B-H, Feng Y, Zhang R, Xu L-H, Li M-Z, Kung H-F, et al. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol Cancer. 2011;10(1):10.PubMedPubMedCentralCrossRef
95.
Huang K, Liu J, Li X, Song L-B, Zeng M-S. Association of Bmi-1 mRNA expression with differentiation, metastasis and prognosis of gastric carcinoma. Nan fang yi ke da xue xue bao. J Southern Med Univ. 2007;27(7):973–5.
96.
Huang D, He X, Zou J, Guo P, Jiang S, Lv N, et al. Negative regulation of Bmi-1 by AMPK and implication in cancer progression. Oncotarget. 2016;7(5):6188.PubMedCrossRef
97.
Chen Q, Ge X, Zhang Y, Xia H, Yuan D, Tang Q, et al. Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. Oncol Rep. 2014;31(4):1863–70.PubMedCrossRef
98.
Patel N, Garikapati KR, Ramaiah MJ, Polavarapu KK, Bhadra U, Bhadra MP. miR-15a/miR-16 induces mitochondrial dependent apoptosis in breast cancer cells by suppressing oncogene BMI1. Life Sci. 2016;164:60–70.PubMedCrossRef
99.
Koh H, Park H, Chandimali N, Huynh DL, Zhang JJ, Ghosh M, et al. MicroRNA-128 suppresses paclitaxel-resistant lung cancer by inhibiting MUC1-C and BMI-1 in cancer stem cells. Oncotarget. 2017;8(66):110540.PubMedPubMedCentralCrossRef
100.
Zhou J, Yang Z, Tsuji T, Gong J, Xie J, Chen C, et al. LITAF and TNFSF15, two downstream targets of AMPK, exert inhibitory effects on tumor growth. Oncogene. 2011;30(16):1892–900.PubMedPubMedCentralCrossRef
101.
Sun R, Ma X, Cai X, Pan X, Liu D. The effect and mechanism of action of metformin on in vitro FaDu cell proliferation. J Int Med Res. 2016;44(5):1049–54.PubMedPubMedCentralCrossRef
102.
Liu J, Lei D-P, Jin T, Zhao X-N, Li G, Pan X-L. Altered expression of miR-21 and PTEN in human laryngeal and hypopharyngeal squamous cell carcinomas. Asian Pacific J Cancer Prevent APJCP. 2011;12(10):2653–7.
103.
Ganci F, Sacconi A, Bossel Ben-Moshe N, Manciocco V, Sperduti I, Strigari L, et al. Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. Ann Oncol. 2013;24(12):3082–8.PubMedPubMedCentralCrossRef
104.
Lee S, Bang S, Song K, Lee I. Differential expression in normal-adenoma-carcinoma sequence suggests complex molecular carcinogenesis in colon. Oncol Rep. 2006;16(4):747–54.PubMed
105.
Jansen AP, Camalier CE, Stark C, Colburn NH. Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. Mol Cancer Ther. 2004;3(2):103–10.PubMedCrossRef
106.
Xu Y-T, Chen R-Q, Lin G-B, Fang X-L, Yu S-J, Liang X-H, et al. Defining the regulatory role of programmed cell death 4 in laryngeal squamous cell carcinoma. Biochem Cell Biol. 2018;96(5):522–38.PubMedCrossRef
107.
Dong J, Peng H, Yang X, Wu W, Zhao Y, Chen D, et al. Metformin mediated microRNA-7 upregulation inhibits growth, migration, and invasion of non-small cell lung cancer A549 cells. Anticancer Drugs. 2020;31(4):345.PubMedPubMedCentralCrossRef
108.
Xiong S, Zheng Y, Jiang P, Liu R, Liu X, Chu Y. MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. Int J Biol Sci. 2011;7(6):805.PubMedPubMedCentralCrossRef
109.
Zeng J, Cai S. Breviscapine suppresses the growth of non-small cell lung cancer by enhancing microRNA-7 expression. J Biosci. 2017;42(1):121–9.PubMedCrossRef
110.
Wang C, Ding M, Xia M, Chen S, Van Le A, Soto-Gil R, et al. A five-miRNA panel identified from a multicentric case–control study serves as a novel diagnostic tool for ethnically diverse non-small-cell lung cancer patients. EBioMedicine. 2015;2(10):1377–85.PubMedPubMedCentralCrossRef
111.
Xiao H. MiR-7-5p suppresses tumor metastasis of non-small cell lung cancer by targeting NOVA2. Cell Mol Biol Lett. 2019;24(1):1–13.CrossRef
112.
Jin D, Guo J, Wu Y, Chen W, Du J, Yang L, et al. Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis. J Exp Clin Cancer Res. 2020;39(1):1–24.CrossRef
113.
Jin D, Guo J, Wang D, Wu Y, Wang X, Gao Y, et al. The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC. EBioMedicine. 2018;37:188–204.PubMedPubMedCentralCrossRef
114.
115.
Zhang Z, Li F, Tian Y, Cao L, Gao Q, Zhang C, et al. Metformin enhances the antitumor activity of CD8+ T lymphocytes via the AMPK-miR-107-Eomes-PD-1 pathway. J Immunol. 2020;204(9):2575–88.PubMedCrossRef
116.
Rao RR, Li Q, Odunsi K, Shrikant PA. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity. 2010;32(1):67–78.PubMedPubMedCentralCrossRef
117.
Zhao R, Song Y, Wang Y, Huang Y, Li Z, Cui Y, et al. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway. Cell Prolif. 2019;52(3):e12571.PubMedPubMedCentralCrossRef
118.
Xia H, Li Y, Lv X. MicroRNA-107 inhibits tumor growth and metastasis by targeting the BDNF-mediated PI3K/AKT pathway in human non-small lung cancer. Int J Oncol. 2016;49(4):1325–33.PubMedPubMedCentralCrossRef
119.
Bao X, Zhao L, Guan H, Li F. Inhibition of LCMR1 and ATG12 by demethylation-activated miR-570-3p is involved in the anti-metastasis effects of metformin on human osteosarcoma. Cell Death Dis. 2018;9(6):1–13.CrossRef
120.
Wang W, Sun J, Li F, Li R, Gu Y, Liu C, et al. A frequent somatic mutation in CD274 3′-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding. Hum Mutat. 2012;33(3):480–4.PubMedCrossRef
121.
Guo W, Tan W, Liu S, Huang X, Lin J, Liang R, et al. MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma. Tumor Biol. 2015;36(11):9049–57.CrossRef
122.
Zheng H, Zhang L, Zhao Y, Yang D, Song F, Wen Y, et al. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS ONE. 2013;8(11):e77853.PubMedPubMedCentralCrossRef
123.
Yu Z, Wang Y, Wang B, Zhai J. Metformin Affects paclitaxel sensitivity of ovarian cancer cells through autophagy mediated by long noncoding RNASNHG7/miR-3127–5p axis. Cancer Biother Radiopharm. 2020.
124.
Jiang J, Zhang Y, Guo Y, Yu C, Chen M, Li Z, et al. MicroRNA-3127 promotes cell proliferation and tumorigenicity in hepatocellular carcinoma by disrupting of PI3K/AKT negative regulation. Oncotarget. 2015;6(8):6359.PubMedPubMedCentralCrossRef
125.
Tang D, Zhao D, Wu Y, Yao R, Zhou L, Lu L, et al. The miR-3127-5p/p-STAT 3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer. J Cell Mol Med. 2018;22(8):3847–56.PubMedCentralCrossRefPubMed
126.
Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA. 2014;311(4):392–404.PubMedCrossRef
127.
Srivastava SK, Bhardwaj A, Singh S, Arora S, Wang B, Grizzle WE, et al. MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. Carcinogenesis. 2011;32(12):1832–9.PubMedPubMedCentralCrossRef
128.
Fa Z, Min Z, Tang J, Liu C, Yan G, Xi J. MicroRNA-150 suppresses the growth and malignant behavior of papillary thyroid carcinoma cells via downregulation of MUC4. Exp Ther Med. 2018;16(1):45–52.PubMedPubMedCentral
129.
Yang K, He M, Cai Z, Ni C, Deng J, Ta N, et al. A decrease in miR-150 regulates the malignancy of pancreatic cancer by targeting c-Myb and MUC4. Pancreas. 2015;44(3):370–9.PubMedCrossRef
130.
Farhana L, Dawson MI, Murshed F, Das JK, Rishi AK, Fontana JA. Upregulation of miR-150* and miR-630 induces apoptosis in pancreatic cancer cells by targeting IGF-1R. PLoS ONE. 2013;8(5):e61015.PubMedPubMedCentralCrossRef
131.
Moser C, Schachtschneider P, Lang SA, Gaumann A, Mori A, Zimmermann J, et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J Cancer. 2008;44(11):1577–86.PubMedCrossRef
132.
Yue W, Zheng X, Lin Y, Yang CS, Xu Q, Carpizo D, et al. Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. Oncotarget. 2015;6(25):21208.PubMedPubMedCentralCrossRef
133.
Rozengurt E, Sinnett-Smith J, Kisfalvi K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res. 2010;16(9):2505–11.PubMedPubMedCentralCrossRef
134.
Kawanami T, Takiguchi S, Ikeda N, Funakoshi A. A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells. Oncol Rep. 2012;27(3):867–72.PubMed
135.
Mannaerts GP, Van Veldhoven PP, Casteels M. Peroxisomal lipid degradation via β-and α-oxidation in mammals. Cell Biochem Biophys. 2000;32(1–3):73–87.PubMedCrossRef
136.
Ma M, Ma C, Li P, Ma C, Ping F, Li W, et al. Low glucose enhanced metformin’s inhibitory effect on pancreatic cancer cells by suppressing glycolysis and inducing energy stress via up-regulation of miR-210-5p. Cell Cycle. 2020;19(17):2168–81.PubMedPubMedCentralCrossRef
137.
Ni H-Z, Liu Z, Sun L-L, Zhou M, Liu C, Li W-D, et al. Metformin inhibits angiogenesis of endothelial progenitor cells via miR-221-mediated p27 expression and autophagy. Future Med Chem. 2019;11(17):2263–72.PubMedCrossRef
138.
Jiang X, Ma N, Wang D, Li F, He R, Li D, et al. Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma. Oncotarget. 2015;6(5):3178.PubMedCrossRef
139.
Kawaguchi T, Komatsu S, Ichikawa D, Morimura R, Tsujiura M, Konishi H, et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer. 2013;108(2):361–9.PubMedPubMedCentralCrossRef
140.
Sarkar S, Dubaybo H, Ali S, Goncalves P, Kollepara SL, Sethi S, et al. Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27kip1, p57kip2, and PUMA. Am J Cancer Res. 2013;3(5):465.PubMedPubMedCentral
141.
Tanaka R, Tomosugi M, Horinaka M, Sowa Y, Sakai T. Metformin causes G1-phase arrest via down-regulation of MiR-221 and enhances TRAIL sensitivity through DR5 up-regulation in pancreatic cancer cells. PLoS ONE. 2015;10(5):e0125779.PubMedPubMedCentralCrossRef
142.
Coleman CB, Lightell DJ Jr, Moss SC, Bates M, Parrino PE, Woods TC. Elevation of miR-221 and-222 in the internal mammary arteries of diabetic subjects and normalization with metformin. Mol Cell Endocrinol. 2013;374(1–2):125–9.PubMedPubMedCentralCrossRef
143.
Qian C, Ye Y, Mao H, Yao L, Sun X, Wang B, et al. Downregulated lncRNA-SNHG1 enhances autophagy and prevents cell death through the miR-221/222/p27/mTOR pathway in Parkinson’s disease. Exp Cell Res. 2019;384(1):111614.PubMedCrossRef
144.
Li L, Wang Z, Hu X, Wan T, Wu H, Jiang W, et al. Human aortic smooth muscle cell-derived exosomal miR-221/222 inhibits autophagy via a PTEN/Akt signaling pathway in human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2016;479(2):343–50.PubMedCrossRef
145.
Shankaraiah RC, Callegari E, Guerriero P, Rimessi A, Pinton P, Gramantieri L, et al. Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. Oncogene. 2019;38(45):7035–45.PubMedCrossRef
146.
Li A, Omura N, Hong S-M, Vincent A, Walter K, Griffith M, et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Can Res. 2010;70(13):5226–37.CrossRef
147.
Bai Z, Sun J, Wang X, Wang H, Pei H, Zhang Z. MicroRNA-153 is a prognostic marker and inhibits cell migration and invasion by targeting SNAI1 in human pancreatic ductal adenocarcinoma. Oncol Rep. 2015;34(2):595–602.PubMedPubMedCentralCrossRef
148.
Sun Y, Zhang T, Wang C, Jin X, Jia C, Yu S, et al. MiRNA-615-5p functions as a tumor suppressor in pancreatic ductal adenocarcinoma by targeting AKT2. PLoS ONE. 2015;10(4):e0119783.PubMedPubMedCentralCrossRef
149.
Yamana H, Kato K, Kobara H, Fujihara S, Fujita K, Namima D, et al. Metformin inhibits proliferation and tumor growth of QGP-1 pancreatic neuroendocrine tumor cells by inducing cell cycle arrest and apoptosis. Anticancer Res. 2020;40(1):121–32.PubMedCrossRef
150.
Yang J, Wei J, Wu Y, Wang Z, Guo Y, Lee P, et al. Metformin induces ER stress-dependent apoptosis through miR-708-5p/NNAT pathway in prostate cancer. Oncogenesis. 2015;4(6):e158-e.CrossRef
151.
Guo P, Lan J, Ge J, Nie Q, Mao Q, Qiu Y. miR-708 acts as a tumor suppressor in human glioblastoma cells. Oncol Rep. 2013;30(2):870–6.PubMedCrossRef
152.
Jang JS, Jeon H-S, Sun Z, Aubry MC, Tang H, Park C-H, et al. Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res. 2012;18(13):3658–67.PubMedPubMedCentralCrossRef
153.
McDonald AC, Vira M, Walter V, Shen J, Raman JD, Sanda MG, et al. Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy. Prostate. 2019;79(9):961–8.PubMedPubMedCentralCrossRef
154.
Chen J, Gu Y, Shen W. MicroRNA-21 functions as an oncogene and promotes cell proliferation and invasion via TIMP3 in renal cancer. Eur Rev Med Pharmacol Sci. 2017;21(20):4566–76.PubMed
155.
Kalogirou C, Schäfer D, Krebs M, Kurz F, Schneider A, Riedmiller H, et al. Metformin-derived growth inhibition in renal cell carcinoma depends on miR-21-mediated PTEN expression. Urol Int. 2016;96(1):106–15.PubMedCrossRef
156.
Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Syrjänen K, Kosma V. Expression of cyclins A and D and p21 (waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival. Br J Cancer. 1999;80(12):2001–7.PubMedPubMedCentralCrossRef
157.
Bera A, Ghosh-Choudhury N, Dey N, Das F, Kasinath BS, Abboud HE, et al. NFκB-mediated cyclin D1 expression by microRNA-21 influences renal cancer cell proliferation. Cell Signal. 2013;25(12):2575–86.PubMedPubMedCentralCrossRef
158.
Connell-Crowley L, Harper JW, Goodrich DW. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell. 1997;8(2):287–301.PubMedPubMedCentralCrossRef
159.
Xie W, Wang L, Sheng H, Qiu J, Zhang D, Zhang L, et al. Metformin induces growth inhibition and cell cycle arrest by upregulating microRNA34a in renal cancer cells. Med Sci Monit Intern Med J Exp Clin Res. 2017;23:29.
160.
Yu G, Li H, Wang J, Gumireddy K, Li A, Yao W, et al. miRNA-34a suppresses cell proliferation and metastasis by targeting CD44 in human renal carcinoma cells. J Urol. 2014;192(4):1229–37.PubMedCrossRef
161.
Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 2008;582(10):1564–8.PubMedCrossRef
162.
163.
Migita T, Oda Y, Naito S, Tsuneyoshi M. Low expression of p27Kip1 is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer. 2002;94(4):973–9.PubMedCrossRef
164.
Zhou X, Kuang Y, Liang S, Wang L. Metformin inhibits cell proliferation in SKM-1 cells via AMPK-mediated cell cycle arrest. J Pharmacol Sci. 2019;141(4):146–52.PubMedCrossRef
165.
Zhuang Y, Miskimins W. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27 Kip1 or p21 Cip1. J Mol Signaling. 2008;3(1):1–11.
166.
Deng Y, Ma W. Metformin inhibits HaCaT cell viability via the miR-21/PTEN/Akt signaling pathway. Mol Med Rep. 2018;17(3):4062–6.PubMed
167.
Wang J, Qiu Y, Shi N, Zhao J, Wang Y, Jiang H, et al. microRNA-21 mediates the TGF-β1-induced migration of keratinocytes via targeting PTEN. Eur Rev Med Pharmacol Sci. 2016;20(18):3748–59.PubMed
168.
Yang X, Wang J, Guo S-L, Fan K-J, Li J, Wang Y-L, et al. miR-21 promotes keratinocyte migration and re-epithelialization during wound healing. Int J Biol Sci. 2011;7(5):685.PubMedPubMedCentralCrossRef
169.
Xiao H, Zhang J, Xu Z, Feng Y, Zhang M, Liu J, et al. Metformin is a novel suppressor for transforming growth factor (TGF)-β1. Sci Rep. 2016;6(1):1–9.
170.
Luo M, Tan X, Mu L, Luo Y, Li R, Deng X, et al. MiRNA-21 mediates the antiangiogenic activity of metformin through targeting PTEN and SMAD7 expression and PI3K/AKT pathway. Sci Rep. 2017;7:43427.PubMedPubMedCentralCrossRef
171.
Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, Goldmann T, et al. HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog (Published in cooperation with the University of Texas MD Anderson Cancer Center). 2007;46(7):503–11.
172.
Sheng Y, Qi S, Hu R, Zhao J, Rui W, Miao Y, et al. Identification of blood microRNA alterations in patients with severe active alopecia areata. J Cell Biochem. 2019;120(9):14421–30.PubMedCrossRef
173.
He X-W, Shi Y-H, Liu Y-S, Li G-F, Zhao R, Hu Y, et al. Increased plasma levels of miR-124-3p, miR-125b-5p and miR-192-5p are associated with outcomes in acute ischaemic stroke patients receiving thrombolysis. Atherosclerosis. 2019;289:36–43.PubMedCrossRef
174.
Chen G, Hu M, Qu X, Wang K, Qu Y. MicroRNA-584 directly targets CCND1 and inhibits cell proliferation and invasion in pancreatic cancer. Mol Med Rep. 2019;19(1):719–26.PubMed
175.
Tseng H-W, Li S-C, Tsai K-W. Metformin treatment suppresses melanoma cell growth and motility through modulation of microRNA expression. Cancers. 2019;11(2):209.PubMedCentralCrossRef
176.
Lei D, Zhang F, Yao D, Xiong N, Jiang X, Zhao H. MiR-338-5p suppresses proliferation, migration, invasion, and promote apoptosis of glioblastoma cells by directly targeting EFEMP1. Biomed Pharmacother. 2017;89:957–65.PubMedCrossRef
177.
Zhang X, Sheng J, Zhang Y, Tian Y, Zhu J, Luo N, et al. Overexpression of SCAMP3 is an indicator of poor prognosis in hepatocellular carcinoma. Oncotarget. 2017;8(65):109247.PubMedPubMedCentralCrossRef
Metadata
Title
How metformin affects various malignancies by means of microRNAs: a brief review
Authors
Nahid Alimoradi
Negar Firouzabadi
Reihaneh Fatehi
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-021-01921-z

Other articles of this Issue 1/2021

Cancer Cell International 1/2021 Go to the issue

Primary research

Overcoming the UCB HSCs –Derived NK cells Dysfunction through Harnessing RAS/MAPK, IGF-1R and TGF-β Signaling Pathways

Review

Triple-negative breast cancer: understanding Wnt signaling in drug resistance

Primary research

Identification of differential proteomics in Epstein-Barr virus-associated gastric cancer and related functional analysis

Primary research

Aurora kinase A (AURKA) promotes the progression and imatinib resistance of advanced gastrointestinal stromal tumors

Correction

Correction to: microRNA-338-3p inhibits proliferation, migration, invasion, and EMT in osteosarcoma cells by targeting activator of 90 kDa heat shock protein ATPase homolog 1

Primary research

CircNEIL3 promotes cervical cancer cell proliferation by adsorbing miR-137 and upregulating KLF12
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits